var title_f2_56_2944="Acute pelvic pain in the postmenarchal adolescent female";
var content_f2_56_2944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 637px\">",
"   <div class=\"ttl\">",
"    Acute pelvic pain in the postmenarchal adolescent female who is not pregnant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 617px; height: 771px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RLQ: right lower quadrant; US: ultrasound; CT: computed tomography; CVA: costovertebral angle; STD: sexually transmitted diseases; PID: pelvic inflammatory disease; DNA: deoxyribonucleic acid.",
"     <br>",
"      * Pelvic examination is suggested for sexually active patients.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       See the topic \"Causes of abdominal pain in children and adolescents\".",
"       <br>",
"        &Delta; Insterstitial cystitis, voiding dysfunction.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2944=[""].join("\n");
var outline_f2_56_2944=null;
var title_f2_56_2945="Ankle fracture complicated by complex regional pain syndrome";
var content_f2_56_2945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ankle fracture complicated by complex regional pain syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early Complex Regional Pain Syndrome (CRPS) in a patient with a lateral avulsion fracture. The patient had been treated with weight bearing as tolerated in a walking cast boot. The patient presented with increased pain, swelling, warmth, and skin changes 23 days after the injury. He responded to gabapentin, early motion, tactile stimulation and sympathetic nerve blockade.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2945=[""].join("\n");
var outline_f2_56_2945=null;
var title_f2_56_2946="Tips for taking HIV medications";
var content_f2_56_2946=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Tips for taking HIV medications (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/56/2946/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2946/contributors\" id=\"au4432\">",
"       Amy L Graziani, PharmD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/56/2946/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2946/contributors\" id=\"se136\">",
"       John G Bartlett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/56/2946/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2946/contributors\" id=\"de8449\">",
"       Allyson Bloom, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/56/2946?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIV TREATMENT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Medications used to treat HIV are called antiretroviral therapy (ART). Patients usually take a combination of three HIV medications, often including a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) or an integrase strand transfer inhibitor (INSTI) plus two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs). Sometimes two or three of these medicines are combined in one tablet. Each class of medication has a specific task, which works best when it is combined with another class of medication. The medication should be refilled regularly and is considered a &ldquo;chronic medication,&rdquo; which means it should be continued indefinitely, providing you are tolerating it well.",
"    </p>",
"    <p>",
"     Most ART regimens require you to take one or more pills per day. Skipping a dose or taking it late can have several possible effects:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The viral load (the amount of HIV in the body) can increase. This can lower your T cell count, which is also called a CD4 count and is a measurement of your immune system. The lower the T cell count, the higher your risk of HIV-related complications or even death.",
"      </li>",
"      <li>",
"       The virus can become resistant to treatment. The likelihood of developing drug resistance depends upon the individual patient, the drugs being taken, and how many pills were missed. Becoming resistant means that the current treatment no longer works and a new medication(s) is required. In some cases, if one medicine stops because of resistance, several other related medicines may also not work. This includes medications that you may never have taken before.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This topic review discusses tips for taking medications correctly and on time so you can avoid treatment failure and drug resistance. Other topic reviews about HIV treatment are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"      \"Patient information: Initial treatment of HIV (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IMPORTANT GENERAL ADVICE",
"     </span>",
"    </p>",
"    <p>",
"     The following tips can help to reduce your risk of developing drug resistance, failed treatment, HIV-related complications, and drug interactions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Remembering to take medications",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Fill a pill organizer once per week to make it easier to take your medications. Keep this box where you will see it.",
"      </li>",
"      <li>",
"       Get in the habit of taking your medications with an activity you do daily (eg, brushing your teeth).",
"      </li>",
"      <li>",
"       Use a cell phone, pager, watch, computer, personal digital assistant (PDA), or other electronic alarm to help remind you to take medications.",
"      </li>",
"      <li>",
"       Keep a back-up supply in a handbag, backpack, or at work, in case you forget your pills. Your healthcare provider may ask you to bring your pill bottles to your visit; this is a good way to be sure that you are taking the correct medication and dose and that your doctor is aware of ALL the medicines you take. Get a written copy of your treatment plan at the end of each visit.",
"      </li>",
"      <li>",
"       If your sleep, work or school schedule, or your responsibilities at home interfere with taking your medication on time, discuss this with your provider. Plan ahead for weekends, vacations, and other changes in your routine.",
"      </li>",
"      <li>",
"       Using alcohol or street drugs can make it hard to remember to take medications on time. Be honest about these issues with your provider before agreeing to a treatment plan.",
"      </li>",
"      <li>",
"       It is important to take all of the medications in your regimen each and every day. Taking only a portion of the HIV medications can lead to resistance. When resistance occurs, that medication is no longer effective against your HIV infection.",
"      </li>",
"      <li>",
"       Call your healthcare provider's office immediately if you have difficulty getting any of your prescriptions filled. Pay attention to renewal notices you get in the mail and requirements for medication insurance coverage. If you think your insurance coverage may be changing or may be terminated, let your provider or social worker know as soon as possible. Check with your provider or social worker if you are thinking about changing your medication insurance plan electively. Some plans may be better than others with respect to HIV medications.",
"      </li>",
"      <li>",
"       Never change the number of pills or stop your pills without speaking with your clinician.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Dealing with side effects",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects with antiretroviral (ART) medications can occur. Many side effects improve over time. You should contact your provider about intolerable side effects. Do not stop your ART regimen until speaking with your provider.",
"      </li>",
"      <li>",
"       There may be times that you are not able to take some of the pills in your regimen, either because you have run out of medication or because of illness (nausea and vomiting). Be sure to discuss this with your healthcare provider.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pharmacy issues",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Check with your pharmacist or healthcare provider immediately if the medications from your pharmacy look different from how they looked previously, or if the dosage is different from what you recall.",
"      </li>",
"      <li>",
"       When you need refills, call your pharmacy several days in advance to be sure they are in stock. Consider using a pharmacy that specializes in HIV medicines; many pharmacies will call once per month to see if you need refills.",
"      </li>",
"      <li>",
"       It is generally better to use one pharmacy for all of your medication needs. If you have to use more than one pharmacy, make sure each pharmacy is aware of all of the medications you are taking.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Hospitalization and HIV medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have to go to the hospital, it is helpful to bring a list of your medications, or even the medications themselves, to be certain that there is no interruption in your schedule. You should give the medications to your physician, nurse or hospital pharmacist. Home medications should not be taken (unless this is advised by the physician) once you are in the hospital.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Other medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some HIV medications can interact with other medicines. For example, garlic supplements, milk thistle and St. John's wort substantially reduce the concentrations of some protease inhibitors. There are some other commonly used medications that can interfere with your HIV medications as well, including those that treat cholesterol, asthma, and heartburn for example. Ask your pharmacist or other healthcare provider to determine if there are any interactions between medications and any other prescription, over-the-counter, or herbal medications that you take.",
"    </p>",
"    <p>",
"     Some HIV medications should be taken at the same time as other HIV medications. For example atazanavir (Reyataz&reg;) and darunavir (Prezista&reg;) must be taken at the same time as ritonavir (Norvir&reg;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      With food or without?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some HIV medications should be taken with food while others must be taken on an empty stomach. An empty stomach is defined as one hour before eating or two hours after. For example, darunavir, atazanavir and rilpivirine (Edurant&reg;, Complera&reg;) should be taken with food to be effective, but efavirenz (Sustiva&reg;, Atripla&reg;) should be taken on an empty stomach or the medicine might be too strong.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804614710\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181960061\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=see_link\">",
"      Patient information: Tests to monitor HIV (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181960096\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37173?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Boosted protease inhibitor monotherapy studies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14774?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33682?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10325?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"      HIV protease inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       CDC (Centers for Disease Control and Prevention) National AIDS Hotline",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;English: (800) 342-2437",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;Spanish: (800) 344-7432",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <span class=\"nowrap\">",
"        HIV/AIDS",
"       </span>",
"       Treatment Information Service",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 448-0440",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hivatis.org/\">",
"      www.hivatis.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       AIDS Clinical Trials Information Service (ACTIS)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 874-2572",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.actis.org/\">",
"      www.actis.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       <span class=\"nowrap\">",
"        HIV/AIDS",
"       </span>",
"       Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://aids.about.com/forum\">",
"      file://aids.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/56/2946/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 18, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/56/2946?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2946/abstract/1\">",
"      Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2946/abstract/2\">",
"      Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2946/abstract/3\">",
"      Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2946/abstract/4\">",
"      Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000; 132:306.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_56_2946=[""].join("\n");
var outline_f2_56_2946=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIV TREATMENT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IMPORTANT GENERAL ADVICE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_56_2947="Patient information: Measles (The Basics)";
var content_f2_56_2947=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83973\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/50/4896\">",
"         Measles rash",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/52/8003\">",
"         Patient information: Vaccines and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/25/39318\">",
"         Patient information: Adult vaccines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Measles (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/measles-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15263622\">",
"      <span class=\"h1\">",
"       What is measles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Measles is an infection that can cause a rash, fever, and cough. It is caused by infection with the measles virus. This virus spreads very easily from person to person.",
"     </p>",
"     <p>",
"      There is a vaccine (that comes in a shot) that keeps people from getting measles. It is called the MMR vaccine. It protects against 3 different infections: measles, mumps, and rubella. People need 2 doses of the MMR vaccine to protect against measles.",
"     </p>",
"     <p>",
"      People who are at risk for measles include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Children too young to get a measles shot",
"       </li>",
"       <li>",
"        People who have never had a measles shot",
"       </li>",
"       <li>",
"        People who did not get a second measles shot",
"       </li>",
"       <li>",
"        People who got a shot that did not work well",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Going to countries where measles shots are not common or being around people from these countries can raise the risk of getting measles.",
"     </p>",
"     <p>",
"      Measles can cause long-term problems with the lungs, ears, or brain. These problems can be dangerous. People can die from measles and the problems it causes.",
"     </p>",
"     <p>",
"      Some people have a higher risk of serious problems from measles. They include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        People with",
"        <span class=\"nowrap\">",
"         HIV/AIDS",
"        </span>",
"        or cancer",
"       </li>",
"       <li>",
"        Pregnant women",
"       </li>",
"       <li>",
"        People who do not get enough food or vitamins",
"       </li>",
"       <li>",
"        Babies",
"       </li>",
"       <li>",
"        Very old people",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263637\">",
"      <span class=\"h1\">",
"       What are the symptoms of measles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The first symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever &ndash; Up to 104&ordm;F (40&ordm;C)",
"       </li>",
"       <li>",
"        Feeling sick, like with a cold",
"       </li>",
"       <li>",
"        Loss of appetite",
"       </li>",
"       <li>",
"        Spots in the mouth &ndash; These can look like grains of salt.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After the first symptoms, many people have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Red, runny eyes. The eyes might also be extra sensitive to bright light.",
"       </li>",
"       <li>",
"        Sneezing and coughing",
"       </li>",
"       <li>",
"        A red rash that starts on the face and spreads to the body (",
"        <a class=\"graphic graphic_picture graphicRef83849 \" href=\"UTD.htm?4/50/4896\">",
"         picture 1",
"        </a>",
"        ). The spots in the rash can form red patches.",
"       </li>",
"       <li>",
"        A sore throat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most people start feeling better about 2 days after the rash starts. After 3 or 4 days, the rash starts to turn brown and go away. The skin might peel or flake off, like after a sunburn. Many people have a cough for 1 or 2 weeks after the rash goes away.",
"     </p>",
"     <p>",
"      Some people who get measles have other symptoms, such as a headache, chest pain, or breathing problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263652\">",
"      <span class=\"h1\">",
"       How does measles spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have not had measles or the MMR vaccine, you can catch measles from an infected person. This can happen if you are around an infected person or go somewhere an infected person has been.",
"     </p>",
"     <p>",
"      A person with measles can start spreading it about 5 days before he or she gets a rash. It can spread for about 4 days after the rash is gone.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263669\">",
"      <span class=\"h1\">",
"       Should I call the doctor or nurse if I think my child or I have measles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you or your child has a fever and rash, call the doctor or nurse. He or she can ask questions and tell you what to do next. Don&rsquo;t go to the doctor&rsquo;s office without calling first. Measles spreads easily, so you could give it to other people at the doctor&rsquo;s office.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263684\">",
"      <span class=\"h1\">",
"       What if I was near someone with measles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you or your child has not had the MMR vaccine, call the doctor or nurse. It might still be possible to avoid getting sick. If you get it soon enough, the vaccine can stop measles or make it less serious. People who cannot get the vaccine can take a medicine that can help keep them from getting sick.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263701\">",
"      <span class=\"h1\">",
"       Is there a test for measles?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse can do blood tests to check for measles. But these tests might not be needed. A doctor or nurse can often tell if a person has measles by doing an exam and learning about the symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263716\">",
"      <span class=\"h1\">",
"       How is measles treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For most people, there is no specific treatment. If you or your child have it, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest.",
"       </li>",
"       <li>",
"        Drink plenty of fluids.",
"       </li>",
"       <li>",
"        Take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        &nbsp;(sample brand names: Tylenol&reg;, Acephen&trade;) to help with fever and aches.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Do not give",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      or medicines that contain aspirin to children younger than 18. In children, aspirin can cause a serious problem called Reye syndrome.",
"     </p>",
"     <p>",
"      Doctors give Vitamin A to some children with measles. If your child needs treatment in the hospital, or has another health condition besides measles, the doctor might give Vitamin A.",
"     </p>",
"     <p>",
"      If measles causes other health problems, such as ear infections, doctors can usually treat them. But a few health problems from measles can be life-threatening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263731\">",
"      <span class=\"h1\">",
"       Can measles be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The MMR vaccine prevents infection.",
"     </p>",
"     <p>",
"      All children should get the MMR vaccine when they are 12 to 15 months old. Then they need a second shot when they are 4 to 6 years old. A child should have the second shot before he or she starts school.",
"     </p>",
"     <p>",
"      Some older children and adults also need the MMR vaccine, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hospital or healthcare workers",
"       </li>",
"       <li>",
"        Students who don&rsquo;t have written proof of 2 shots &nbsp;",
"       </li>",
"       <li>",
"        People traveling outside the United States who don&rsquo;t have written proof of 1 shot",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people in the US got a vaccine that did not work well. If you got a measles shot before 1968, talk to your doctor or nurse.",
"     </p>",
"     <p>",
"      Some people should wait or get tested before getting the MMR vaccine. This includes people with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      or cancer and people taking certain medicines.",
"     </p>",
"     <p>",
"      The MMR vaccine has a small amount of gelatin and an antibiotic. If you or your child have any allergies, or had a bad reaction to a vaccine, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263746\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, be sure your MMR vaccine is up to date. This means knowing if you got it in the past. If you are not sure, your doctor or nurse can do a blood test to check.",
"     </p>",
"     <p>",
"      Getting measles when you are pregnant could cause a miscarriage. This is when a pregnancy ends before a woman has been pregnant for 20 weeks. Or the baby could be born too early. Babies who are born early can have serious life-long health problems.",
"     </p>",
"     <p>",
"      The MMR vaccine must be given before pregnancy. After you get it, wait at least 4 weeks before trying to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15263761\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/52/8003?source=see_link\">",
"       Patient information: Vaccines and pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       Patient information: Adult vaccines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/56/2947?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83973 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2947=[""].join("\n");
var outline_f2_56_2947=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263622\">",
"      What is measles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263637\">",
"      What are the symptoms of measles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263652\">",
"      How does measles spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263669\">",
"      Should I call the doctor or nurse if I think my child or I have measles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263684\">",
"      What if I was near someone with measles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263701\">",
"      Is there a test for measles?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263716\">",
"      How is measles treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263731\">",
"      Can measles be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263746\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15263761\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/50/4896\">",
"      Measles rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/52/8003?source=related_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_56_2948="Nodular sclerosis Hodgkin lymphoma";
var content_f2_56_2948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular sclerosis Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 213px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Broad bands of fibrosis separate several nodules in nodular sclerosis Hodgkin lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al, Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2948=[""].join("\n");
var outline_f2_56_2948=null;
var title_f2_56_2949="Photon plan EFT paranas sinus";
var content_f2_56_2949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conformal photon beam radiation treatment plans for a young man with a Ewing's sarcoma involving the left paranasal sinuses and infratemporal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast this treatment plan with the proton beam treatment plan illustrated in Figure 1A to see the much higher degree of conformality and normal tissue sparing with protons.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John A Jackson, Medical Dosimetrist, Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2949=[""].join("\n");
var outline_f2_56_2949=null;
var title_f2_56_2950="Function of C1 inhibitor";
var content_f2_56_2950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Function of the C1 inhibitor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 574px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    C1 inhibitor (a serpin or serine protease inhibitor) interferes with the activation of the classical complement pathway by binding to and inactivating the serine protease subcomponents of C1, C1r, and C1s. In this process, C1r/C1s: C1-inhibitor complex dissociates from the C1q subcomponent of C1 which remains bound to the immune-complex. Note that C1-inhibitor also regulates in the same manner the mannan-associated serine proteases (MASPs) that are the C1r/C1s equivalents in the lectin pathway of complement activation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2950=[""].join("\n");
var outline_f2_56_2950=null;
var title_f2_56_2951="Asenapine: Drug information";
var content_f2_56_2951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Asenapine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/1/30741?source=see_link\">",
"    see \"Asenapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11238844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8061396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Saphris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14942057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Saphris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8061948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimanic Agent;",
"     </li>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9469985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Safety of doses &gt;20 mg/day has not been evaluated:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute treatment:",
"     </i>",
"     Initial: 5 mg twice daily. Daily doses &gt;20 mg/day in clinical trials did not appear to offer any additional benefits and increased risk of adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Maintenance treatment:",
"     </i>",
"     Initial: 5 mg twice daily; may increase to 10 mg twice daily after 1 week based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bipolar disorder:",
"     </b>",
"     Sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Monotherapy:",
"     </i>",
"     Initial: 10 mg twice daily; decrease to 5 mg twice daily if dose not tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Combination therapy (with lithium or valproate):",
"     </i>",
"     5 mg twice daily; may increase to 10 mg twice daily based on tolerability",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9469986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9469987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9469988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment is necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe hepatic impairment (Child-Pugh class C): Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9469994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saphris&reg;: 5 mg [unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saphris&reg;: 5 mg [black cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saphris&reg;: 10 mg [unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saphris&reg;: 10 mg [black cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9469990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sublingual tablets should be placed under the tongue and allowed to disintegrate. Do not crush, chew, or swallow. Avoid eating or drinking for at least 10 minutes after administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8061949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute and maintenance treatment of schizophrenia; treatment of acute mania or mixed episodes associated with bipolar I disorder (as monotherapy or in combination with lithium or valproate)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13930945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9469955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actual frequency may be dependent upon dose and/or indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Somnolence (13% to 24%), insomnia (6% to 16%), extrapyramidal symptoms (6% to 12%), headache (12%), akathisia (4% to 11%; dose related), dizziness (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (13% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (2% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular and skeletal: Creatine kinase increased (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (3%), hypertension (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Hypoesthesia (4% to 7%), fatigue (3% to 4%), anxiety (4%), depression (2%), irritability (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Cholesterol increased (8% to 9%), glucose increased (5% to 7%), hyperprolactinemia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (4% to 7%), vomiting (4% to 7%), dyspepsia (3% to 4%), appetite increased (&le;4%), salivation increased (&le;4%), abnormal taste (3%), toothache (3%), abdominal discomfort (&le;3%), xerostomia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (&lt;1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (3%), extremity pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, anemia, angioedema, bradycardia, bundle branch block (temporary), dystonia, hypersensitivity, hyponatremia, hypotension, idiosyncratic drug reaction, leukopenia, mucosal lesions, neuroleptic malignant syndrome, neutropenia, ocular accommodation disorder, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, seizures, syncope, tachycardia, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9469950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to asenapine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9469951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse reactions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of antipsychotics for the unapproved use in elderly patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyslipidemia: Has been reported with atypical antipsychotics; risk profile may differ between agents. In clinical trials, the incidence of hypertriglyceridemia observed with asenapine was greater than that observed with placebo, while total cholesterol elevations were similar.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of aspiration pneumonia (eg, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause EPS, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Anaphylaxis and hypersensitivity reactions (eg, angioedema, hypotension, tachycardia) have been reported; some cases have occurred after a single dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect (eg, concurrent medication use which may predispose to hypotension/bradycardia or presence of hypovolemia) or in those who would not tolerate transient hypotensive episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: May result in QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation. Risk may be increased by conditions or concomitant medications which cause bradycardia, hypokalemia, and/or hypomagnesemia. Avoid use in combination with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs and in patients with congenital long QT syndrome or patients with history of cardiac arrhythmia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating; use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiac disease, cerebrovascular disease, hemodynamic instability, prior myocardial infarction, or ischemic heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Asenapine is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use not recommended in patients with severe hepatic impairment; increased drug concentrations may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Elevates prolactin levels; effects seen in adults and children. Use with caution in breast cancer or other prolactin-dependent tumors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria). Pharmacokinetic studies showed a decrease in clearance in older adults (65-85 years of age) with psychosis compared to younger adults; increased risk of adverse effects and orthostasis may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9518188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Asenapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Asenapine may increase the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9469964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9469946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9469947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies indicate an increased risk of fetal mortality. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the benefits justify the risk to the fetus. Healthcare providers are encouraged to enroll women 18-45 years of age exposed to asenapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry  (866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9469949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9469989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid eating or drinking for at least 10 minutes after administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Saphris Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (10): $137.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (10): $137.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9469992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Vital signs; fasting lipid profile and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (baseline and periodically); CBC frequently during first few months of therapy in patients with pre-existing low WBC or a history of drug-induced leukopenia/neutropenia; BMI, personal/family history of obesity, waist circumference; blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms; orthostatic blood pressure changes for 3-5 days after starting or increasing dose. Weight should be assessed prior to treatment and regularly throughout therapy. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Saphris (BR, MY, SG);",
"     </li>",
"     <li>",
"      Sycrest (BE, CZ, DE, DK, EE, GB, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9469967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Asenapine is a dibenzo-oxepino pyrrole atypical antipsychotic with mixed serotonin-dopamine antagonist activity. It exhibits high affinity for 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      5-7",
"     </sub>",
"     , D",
"     <sub>",
"      1-4",
"     </sub>",
"     , H",
"     <sub>",
"      1",
"     </sub>",
"     and, alpha",
"     <sub>",
"      1",
"     </sub>",
"     - and alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors; moderate affinity for H",
"     <sub>",
"      2",
"     </sub>",
"     receptors. Asenapine has no significant affinity for muscarinic receptors. The binding affinity to the D",
"     <sub>",
"      2",
"     </sub>",
"     receptor is 19 times lower than the 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     affinity (Weber, 2009). The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects as compared to typical antipsychotics.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9469969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~20-25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 95% (including albumin and &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP1A2 oxidation and UGT1A4 glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Sublingual: 35%; decreased if swallowed (&lt;2%); decreased if administered with food or liquid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~50%); feces (~40%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/56/2951/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon L, Perkins D, and Calmes C,",
"      <i>",
"       Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia",
"      </i>",
"      , Arlington, Va: American Psychiatric Association, 2009. Available at  file://www.psychiatryonline.com/content.aspx?aid=501001",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/56/2951/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Potkin SG, Cohen M, and Panagides J. &ldquo;Efficacy and Tolerability of Asenapine in Acute Schizophrenia: A Placebo- and Risperidone-Controlled Trial,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2007, 68(10):1492-1500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/56/2951/abstract-text/17960962/pubmed\" id=\"17960962\" target=\"_blank\">",
"        17960962",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weber J and McCormack PL, &ldquo;Asenapine,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2009, 23(9):781-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/56/2951/abstract-text/19689168/pubmed\" id=\"19689168\" target=\"_blank\">",
"        19689168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8630 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-512E5AB897-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2951=[""].join("\n");
var outline_f2_56_2951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238844\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8061396\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14942057\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8061948\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469985\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469986\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469987\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469988\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469994\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469990\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8061949\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930945\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469955\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469950\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469951\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298778\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518188\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469964\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469946\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469947\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469949\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469989\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322656\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469992\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390241\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469967\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9469969\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8630|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/1/30741?source=related_link\">",
"      Asenapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_56_2952="WHO weight for age girls 0 to 24 months";
var content_f2_56_2952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63877%7EPEDS%2F53325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63877%7EPEDS%2F53325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 532px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 689px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2952=[""].join("\n");
var outline_f2_56_2952=null;
var title_f2_56_2953="Clinical manifestations and treatment of the hypermobility syndrome";
var content_f2_56_2953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and treatment of the hypermobility syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Robert P Sheon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Rodney Grahame, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Alan J Hakim, BA MB BChir",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2953/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/56/2953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first known reference to joint laxity is attributed to Hippocrates who, in the 4th century BCE, described the Scythians as being &ldquo;so-loose-limbed that they were unable to draw a bow-string or hurl a javelin&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinical features suggestive of hypermobility syndrome and a positive Trendelenburg sign are described in a painting &ldquo;The Three Graces&rdquo; (1638 to 1640) by Peter Paul Rubens, Prado, Madrid. The most obvious findings are scoliosis, positive Trendelenburg sign, hyperextension of the metacarpal joints, hyperlordosis, and flat feet. The sitters, presumably Helene Fourment (second wife of Rubens) and her sisters, support the hereditary familial aspect of hypermobility [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some people have one or a few hypermobile joints; fewer have generalized joint hypermobility, as defined below. Generalized joint hypermobility may be an indicator of a potentially serious disease of connective tissue (eg, Marfan syndrome or Ehlers-Danlos syndromes). Among people with hypermobile joints, many are asymptomatic and have no other recognized disease of connective tissue. However, others with hypermobile joints have symptoms, which may include pain (musculoskeletal and neuropathic), cardiovascular autonomic disturbance, bowel disturbances, profound fatigue, anxiety, and problems related to connective tissue laxity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/3\">",
"     3",
"    </a>",
"    ]. In many respects, these features, which constitute the joint hypermobility syndrome (JHS), are similar if not identical to the more common variant of Ehlers-Danlos syndrome (EDS) (ie, EDS-Hypermobility type [EDS-HM], formerly termed EDS type III). Indeed many experts consider JHS and EDS-HM to be parts of a spectrum of the same condition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews hypermobility of the joints in patients who do not have another of the more rare well-characterized diseases of connective tissue. Clinical manifestations and treatment of the Marfan syndrome, as well as aneurysmal dilation of the thoracic aorta and its complications, which may result from the Marfan syndrome and from vascular forms of EDS, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Joint hypermobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;What constitutes a hypermobile joint? Operationally speaking, it is the ability to painlessly perform maneuvers beyond the normal range of movement. This may occur in any joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Beighton hypermobility score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Beighton hypermobility score is widely used in assessing hypermobility of peripheral joints and the spine. It is the scoring system most often used in epidemiological research. One point is awarded for the ability to perform each of four maneuvers (bilaterally), including passive apposition of the thumb to the forearm, passive hyperextension of fingers, active hyperextension of the elbow &gt;10 degrees, and active hyper extension of the knee &gt;10 degrees (",
"    <a class=\"graphic graphic_table graphicRef78462 \" href=\"UTD.htm?29/6/29803\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61525 graphicRef62841 graphicRef67020 graphicRef81152 \" href=\"UTD.htm?25/59/26548\">",
"     picture 1A-D",
"    </a>",
"    ); additionally, one point is awarded for having an unusually flexible spine, as indicated by the ability to flex the spine with placement of the palms to the floor without bending the knees (",
"    <a class=\"graphic graphic_table graphicRef78462 \" href=\"UTD.htm?29/6/29803\">",
"     table 1",
"    </a>",
"    ). A total of nine points is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Generalized joint hypermobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of generalized joint hypermobility is also an operational one. A Beighton score of greater than or equal to four is considered indicative of generalized hypermobility. Although this and other tests for joint hypermobility perform relatively well in clinical reproducibility studies, further research on the validity of tests and criteria for generalized joint hypermobility and for the benign joint hypermobility syndrome (see below) are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, it is important to assess all the joints from the jaw and cervical spine to the ankles and feet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Joint hypermobility syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;hypermobility syndrome&rdquo; was first used by Kirk, Ansell, and Bywaters in 1967 to describe a disorder in which musculoskeletal pain and generalized joint hypermobility occurred together [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/6\">",
"     6",
"    </a>",
"    ]. The term benign joint hypermobility syndrome (BJHS) has been used in order to distinguish this symptomatic but not life-threatening disorder from diseases such as the Marfan syndrome and certain types of Ehlers-Danlos syndrome in which aortic or other arterial dissections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aneurysms develop. Some question just how benign this disorder is [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/7\">",
"     7",
"    </a>",
"    ]. We will use JHS as a short hand for the presence of otherwise unexplained symptoms and generalized joint hypermobility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevalence of generalized hypermobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of joint hypermobility affecting a few joints is substantial. This was illustrated in a study of 123 healthy medical students in which 22 (18 percent) had at least one lax joint and 14 others (11 percent) had three or more lax joints [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/8\">",
"     8",
"    </a>",
"    ]. Joint laxity is more common in the right limb, in females, in blacks, and in children from families with higher socioeconomic status.",
"   </p>",
"   <p>",
"    The prevalence of generalized joint hypermobility varies from 10 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Generalized laxity is particularly prevalent among elite ballet dancers, being present in nearly one-half of such individuals in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of generalized joint hypermobility decreases with age, and, among postmenopausal Caucasian women, generalized joint hypermobility is infrequent. In one study of 716 such women in the United Kingdom, only one had a Beighton score of four, indicative of widespread joint laxity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevalence of JHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of JHS is less certain. One study of New Zealanders of indigenous or European ancestry found symptoms and generalized joint hypermobility in 0.72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/11\">",
"     11",
"    </a>",
"    ]. In one Canadian rheumatology clinic, hypermobility was noted in 50 of 378 consecutive patients (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/15\">",
"     15",
"    </a>",
"    ]. Our experience in a private rheumatology practice suggests that JHS is as common as rheumatoid arthritis, a disease that affects approximately 1 percent of the population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mobility of joints is limited by the extensibility of structures such as the joint capsule, ligaments, and tendons. The major protein that contributes to the tensile strength of these structures is collagen. Generalized hypermobility is thought to be a disorder of collagen that contributes to a loss of tensile strength and to consequent increased fragility of involved tissues. Support for a substantial genetic component is seen in the higher concordance of joint hypermobility between female monozygotic as opposed to dizygotic twins; in one study, concordance rates of 60 versus 36 percent, respectively, were noted, suggesting that a heritable trait contributes to 70 percent of the variance seen in joint hypermobility [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint laxity as an inherited cause for congenital joint dislocation has been reported many times since the early 1900s [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/17\">",
"     17",
"    </a>",
"    ]. These associations are rare, however, when compared with the much more common benign hypermobility syndrome.",
"   </p>",
"   <p>",
"    Some patients with JHS may have a deficiency of a matrix protein, tenascin-X. Absence of tenascin-X, due to homozygous tenascin-X gene (TNXB) mutations or deletions, has been associated with a disorder with many characteristics of the hypermobile type of Ehlers-Danlos syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/18\">",
"     18",
"    </a>",
"    ]. Five affected patients manifested hyperextensible skin, hypermobile joints, and tissue fragility with easy bruising. Among family members who were heterozygous for the responsible TNXB gene defects, 45 percent had generalized joint hypermobility without other features of Ehlers-Danlos syndrome. The prevalence of markedly decreased serum levels of a fragment of tenascin-X (a possible surrogate marker for TNXB haplodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/19\">",
"     19",
"    </a>",
"    ]) appears to be similar in patients with the hypermobile type of Ehlers-Danlos syndrome and in Dutch patients with JHS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While, mutations in the TNXB gene may be responsible for hypermobile joints in some patients, the cause of generalized joint hypermobility in most affected people is unknown and is suspected to be a polygenic trait.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations that have been associated with JHS include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Musculoskeletal complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with JHS present with a wide variety of traumatic and overuse conditions. They may, for example, have a history of joint &ldquo;swelling&rdquo; that lasts for too brief a period for inflammation, of symmetrical joint pain during use that is relieved with rest, and of arthralgias and myalgias without any other apparent abnormality. The symptoms often are discounted if hypermobility is not observed during the physical examination. Articular symptoms often begin following an illness, pregnancy, or prolonged sedentary activity that has caused a loss of limb strength and physical deconditioning. Equally, they may be present because of recurrent articular soft tissue injuries with subluxation or dislocation.",
"   </p>",
"   <p>",
"    Osteoarthritis (OA) may be more frequent in older patients who have joint laxity, and chondrocalcinosis OA and precocious OA appear to occur with increased frequency in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, the presence of hypermobility in childhood does not necessarily confer an increased risk of OA of the hands later in life; indeed, joint hypermobility may confer a modest reduction in the risk of osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Extraarticular associations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other manifestations of lax connective tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraarticular tissues and organs that rely upon the tensile strength of normal collagen may be affected in patients with JHS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The skin may be soft and may develop striae.",
"     </li>",
"     <li>",
"      Upper eyelids may be lax [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Weakness in abdominal and pelvic floor support may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/7\">",
"       7",
"      </a>",
"      ]. Mechanical bowel pathologies include herniation, gastroesophageal reflux, and megacolon with sluggish passage of feces and constipation. Prolapse of the pelvic wall may give rise to urinary dysfunction such as stress incontinence.",
"     </li>",
"     <li>",
"      An association with mitral valve prolapse has been reported, although studies have yielded conflicting results. In one study, for example, mitral valve prolapse was found significantly more often in patients with the hypermobility syndrome than in age- and symptom-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/26\">",
"       26",
"      </a>",
"      ]. In another study of Japanese patients with echocardiographically documented anterior mitral valve prolapse, a significantly greater proportion had generalized joint hypermobility than did healthy, demographically similar controls without mitral valve prolapse (46 versus 12 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, another study of patients with hypermobility found no evidence of this association [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/28\">",
"       28",
"      </a>",
"      ]. Hypermobility was noted in 31 of 637 healthy blood donors (5 percent); no increased prevalence of arthritis, arthralgia, or cardiac abnormalities was found when these 31 hypermobile subjects were compared with an age- and sex-matched two-for-one control group.",
"     </li>",
"     <li>",
"      A Marfanoid habitus has been described in some patients with JHS. One series noted that 39 percent of patients had a Marfanoid habitus compared with 11.5 percent of controls [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, a Marfanoid syndrome has been described that is characterized by features of Marfan syndrome and of Ehlers-Danlos syndrome such as joint laxity, cardiac valvular lesions, symmetrical striae, and a high arched palate [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. In our experience, however, we have not seen any serious cardiac abnormalities in patients with joint laxity, a high arched palate, and striae.",
"     </li>",
"     <li>",
"      Back pain is also frequent in patients with joint laxity. The &ldquo;loose back&rdquo; has been reported as a common and often unrecognized cause for backache, particularly among women. One study, for example, evaluated 102 consecutive cases of problem back patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/31\">",
"       31",
"      </a>",
"      ]. All but 17 of the 59 males had disc or other skeletal lesions. Among those 17 men, three had one or more lax joints. Of the 43 female patients, 20 had no discernible cause for backache. While two women with a definable back condition also had joint laxity, 17 of the 20 without another cause for backache had joint laxity. This possible association of joint laxity with backache in women has also been recognized in several industrial centers in Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/31\">",
"       31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Joint laxity is an asset in jobs that require changing of body posture. However, because of the development of back pain, hypermobility was found to be a liability in jobs that require sitting or standing for long periods [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients with hypermobility syndrome have additional features of fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/15,33,34\">",
"       15,33,34",
"      </a>",
"      ]. This was illustrated in a study of 378 consecutive patients seen in a rheumatology clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/15\">",
"       15",
"      </a>",
"      ]. Among the 50 patients (13 percent) who had generalized joint hypermobility, the most frequent specific diagnosis was fibromyalgia. This disorder, characterized by chronic widespread pain and multiple tender points, was present in 30 percent of those with joint hypermobility versus 8 percent of other patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"      </a>",
"      .) Patients with both disorders may have the axial pain of fibromyalgia and the peripheral joint complaints of the hypermobility syndrome.",
"     </li>",
"     <li>",
"      Temporomandibular joint (TMJ) disorders are common in patients with hypermobility syndrome. However, studies conflict as to a causal relation to TMJ pain [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Carpal tunnel syndrome (CTS) may occur more commonly in patients with JHS. This was illustrated in a study in which 55 of 90 patients with JHS had carpal tunnel syndrome. In patients with CTS, the mean Beighton scores in those with and without CTS were significantly different (mean Beighton Score of two versus one, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various symptoms are more prevalent in patients with JHS, including symptoms of psychological distress, as well as increased frequency and intensity of somatic symptoms compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/38\">",
"     38",
"    </a>",
"    ]. Disordered autonomic nervous system function due to chronic pain has been postulated as one possible explanation for some of these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the extraarticular manifestations that have been suggested to be associated with JHS are the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety",
"     </li>",
"     <li>",
"      Panic attacks",
"     </li>",
"     <li>",
"      Cognitive disorders (eg, poor concentration, impaired memory)",
"     </li>",
"     <li>",
"      Palpitations (eg, postural orthostatic tachycardia syndrome)",
"     </li>",
"     <li>",
"      Chest discomfort",
"     </li>",
"     <li>",
"      Shortness of breath",
"     </li>",
"     <li>",
"      Tremulousness",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Orthostatic symptoms of hypotension (syncope, blurred vision)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, many people with generalized hypermobility are otherwise healthy and have no symptoms referable to their hypermobile joints. Thus, one should be cautious in ascribing symptoms to joint hypermobility without a careful evaluation for other causes. In addition, generalized joint hypermobility is a feature of other diseases, some of which may have life-threatening manifestations and, thus, should be considered and excluded. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A set of criteria, which incorporate the Beighton score of joint hypermobility, as well as selected symptoms and findings that may occur in JHS, may be used to diagnose JHS, once other causes of symptoms and more serious diseases associated with hypermobile joints have been excluded (",
"    <a class=\"graphic graphic_table graphicRef81835 \" href=\"UTD.htm?32/25/33179\">",
"     table 2",
"    </a>",
"    ). The diagnosis of JHS may be made if the patient fulfills two major criteria or one major and two minor criteria from a specified list [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/21,26,43-45\">",
"     21,26,43-45",
"    </a>",
"    ]. The Beighton hypermobility score (",
"    <a class=\"graphic graphic_table graphicRef78462 \" href=\"UTD.htm?29/6/29803\">",
"     table 1",
"    </a>",
"    ), used as a determinant of the major and minor criteria related to joint mobility, is discussed in more detail above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Joint hypermobility'",
"    </a>",
"    above.) Beighton scores of four to six points are usually found in symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no diagnostically helpful laboratory tests or imaging studies for JHS. However, such testing may be useful to exclude other causes of symptoms or diseases causing joint hypermobility.",
"   </p>",
"   <p>",
"    For adolescents, a goniometric quantitative measurement technique has been devised to assist in measurement and diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis may be difficult to establish in children, who have a greater degree of joint laxity than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/48\">",
"     48",
"    </a>",
"    ]. This was illustrated in a retrospective review of 125 children with hypermobility syndrome cared for at a single tertiary center [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/49\">",
"     49",
"    </a>",
"    ]. The average age at onset of symptoms was 6.2 years, and the average age at diagnosis was nine years. Other clinical features were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major presenting symptoms included arthralgia (74 percent), abnormal gait (10 percent), apparent joint deformity (10 percent), and back pain (6 percent).",
"     </li>",
"     <li>",
"      Many patients had a history of being clumsy (48 percent) or of having poor coordination earlier in childhood (36 percent). Overall, the mean age at first walking was 15 months of age.",
"     </li>",
"     <li>",
"      There were significant difficulties in school with limitations in physical education classes (48 percent), school absences (41 percent), and problems with handwriting tasks (40 percent).",
"     </li>",
"     <li>",
"      On physical examination, 94 percent of the patients had a Beighton score of greater than or equal to four, indicating generalized hypermobility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &ldquo;Growing pains&rdquo; have been ascribed to hypermobility. These predominantly lower extremity, nonarticular, episodic, and, sometimes, severe pains have no clearly established etiology. In a study of 433 Indian children, the prevalence of hypermobility was 41 percent, and the prevalence of growing pains was 28 percent. Having hypermobility significantly increased the risk of having growing pains (odds ratio 3.3, 95% CI 1.8-4.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=see_link\">",
"     \"Growing pains\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As already mentioned, diseases that have generalized joint laxity as a clinical feature are included in the differential diagnosis of JHS (",
"    <a class=\"graphic graphic_table graphicRef72776 \" href=\"UTD.htm?18/39/19067\">",
"     table 3",
"    </a>",
"    ). Each of those disorders, with the exception of the hypermobile type of Ehlers-Danlos syndrome, has one or more characteristic features that serve to distinguish it from the JHS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Marfan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a variable phenotypic expression of Marfan syndrome, there are certain features involving the skeletal, cardiovascular, and ocular systems that are considered major manifestations of the disease. Summarized briefly, they include reduced upper to lower body segment ratio (0.85 versus 0.93 in normals), arm span exceeding height (ratio &gt;1.05), arachnodactyly of fingers and toes, scoliosis, kyphosis, dilation of the aorta proximal aorta, aortic dissection, ectopia lentis, or dural ectasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link&amp;anchor=H10#H10\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\", section on 'Older criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ehlers-Danlos syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ehlers-Danlos syndrome includes a group of conditions generally characterized by hyperelasticity and fragility of the skin and by hypermobility of the joints. Spontaneous rupture of large- and medium-sized arteries, usually without dissection, is the most serious cardiovascular complication and is seen in the vascular type of Ehlers-Danlos syndrome (previously type IV).",
"   </p>",
"   <p>",
"    Excessive laxity of the skin and atrophic (cigarette paper-like) scarring are features of many types of Ehlers-Danlos syndrome, but these cutaneous findings are often less prominent in the hypermobile type of Ehlers-Danlos syndrome (previously type III). In the absence of skin findings, hypermobility type Ehlers-Danlos syndrome cannot be distinguished from JHS. Skin hyperextensibility, although considered an easily performed test in differentiating Ehlers-Danlos syndrome from other causes of joint hypermobility, has been shown to have poor interobserver reliability. Test instruments with more objectivity are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a diagnosis of Ehlers-Danlos syndrome other than the hypermobility type is suspected, diagnosis may be made by genetic testing or by analysis of collagen obtained from cultured fibroblasts following skin biopsy. A resource on genetic disorders, which includes detailed genetic and other information regarding each individual type of Ehlers-Danlos syndrome, is the Online Mendelian Inheritance in Man (OMIM) website [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the prevalence of joint hypermobility, there is a paucity of large cohort comparative data on treatment of JHS. Management advice is based primarily upon fundamental principles of rehabilitation adapted to account for the hypermobility and upon the results of studies of treatment of other noncancer chronic pain disorders. Nonpharmacologic and pharmacologic approaches may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/40,43,54,55\">",
"     40,43,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;When JHS occurs, it is essential to explain to the patients the nature of the condition and to reassure them that they do not have one of the other forms of connective tissue disorder. For many patients, the management back to better function and reduced pain is through a physical conditioning program. Referral for an individualized muscle strengthening and joint protection program to a rehabilitation medicine specialist or to occupational and physical therapists who have expertise in treating patients with hypermobility-related conditions may be appropriate.",
"   </p>",
"   <p>",
"    The importance of proper body mechanics and the value of joint protection for this condition should be emphasized, since these measures are likely to reduce pain and disability. Patients should be warned to respect pain during repetitive activities. Those whose attitude is &ldquo;I&rsquo;m going to finish this even if it kills me&rdquo; may cause cartilage injury due to joint laxity and overuse.",
"   </p>",
"   <p>",
"    Since these patients can assume unusual sitting, lying, and resting body positions, the clinician should review each of these positions with the patient. In particular, patients with hypermobility should not sit with knees tucked under them or in Indian style. Proper shoes should be recommended if pes planus is present.",
"   </p>",
"   <p>",
"    Patient education in good sleep hygiene, coping skills, and relaxation techniques are useful in other chronic pain disorders and may be recommended to those with JHS. Referral to a psychologist skilled in cognitive behavioral therapy may help patients with chronic pain due to JHS, particularly those who also have fibromyalgia, anxiety, or panic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Braces and orthoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, muscle strengthening and patient education in posture and joint protection are preferred to the use of braces. However, use of a patellar restraining brace is sometimes necessary for those with patellar subluxation or for those with marked genu recurvatum. If lower limb pain during walking is not relieved by simple sleeve bracing and strengthening, orthopedic consultation should be considered in order to exclude internal knee derangements. Proper bracing will depend upon the pain pattern, the physical findings, and the goals of the patient, particularly sport or running activities. Studies on knee bracing are conflicting.",
"   </p>",
"   <p>",
"    Orthotics are recommended for those with instability of the foot and ankle based upon their usefulness in correcting poor biomechanics that may contribute to knee, hip, or back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Muscle strengthening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of individualized resistance exercise to forearm extensors, quadriceps, and abdominal muscles has been helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37508?source=see_link\">",
"     \"Joint protection program for the upper limb\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=see_link\">",
"     \"Joint protection program for the lower limb\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral to a physical therapist and occupational therapist may be very beneficial. We find that aquatic exercises can be very helpful to begin reconditioning in severely deconditioned patients and in those who also have fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications include nonsteroidal antiinflammatory drugs (NSAIDs) for those with lower limb pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2953/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, patients with mitral valve prolapse should be considered for antibiotic prophylaxis and for evaluation and treatment of associated arrhythmias, if present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with more widespread pain and those who have fibromyalgia may benefit from pharmacologic approaches that are effective in chronic pain management. The use of these drugs in fibromyalgia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/60/15298?source=see_link\">",
"       \"Patient information: Ehlers-Danlos syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229030\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of joint hypermobility can be detected on initial screening by use of the Beighton hypermobility score, which assigns points for exceeding specified limits of painless range of motion in certain joints and the spine on a 0 to 9 scale (",
"      <a class=\"graphic graphic_table graphicRef78462 \" href=\"UTD.htm?29/6/29803\">",
"       table 1",
"      </a>",
"      ). A Beighton score of greater than or equal to four is indicative of generalized hypermobility. However, any joints may be affected. The term joint hypermobility syndrome (JHS) has been used to distinguish this symptomatic but not life-threatening disorder, in which musculoskeletal pain and generalized joint hypermobility occur, from diseases such as Marfan syndrome and certain types of Ehlers-Danlos syndrome, in which aortic or other arterial dissections",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aneurysms develop. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of joint hypermobility affecting a few joints is substantial, and prevalence estimates of generalized joint hypermobility have varied from 10 to 30 percent but decrease with age. The prevalence of JHS is less certain but may be approximately 1 percent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Generalized hypermobility is thought to be a disorder of collagen that contributes to a loss of tensile strength and to consequent increased fragility of involved tissues. Some patients with JHS may have a deficiency of a matrix protein, tenascin-X. Absence of tenascin-X, due to homozygous tenascin-X gene mutations or deletions, has been associated with a disorder with many characteristics of the hypermobile type of Ehlers-Danlos syndrome. However, the cause of generalized joint hypermobility in most affected people is unknown and is suspected to be a polygenic trait. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of clinical manifestations have been associated with JHS, including a variety of traumatic and overuse conditions. Patients may report transient joint swelling, symmetrical joint pain during use that is relieved with rest, arthralgias and myalgias without any other apparent abnormality, back pain, anxiety, and somatic symptoms. Other findings may affect extraarticular tissues and organs that rely upon the tensile strength of normal collagen, such as the skin. An association with mitral valve prolapse is uncertain, and fibromyalgia can occur in some patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A set of criteria (",
"      <a class=\"graphic graphic_table graphicRef81835 \" href=\"UTD.htm?32/25/33179\">",
"       table 2",
"      </a>",
"      ), which incorporates the Beighton score of joint hypermobility (",
"      <a class=\"graphic graphic_table graphicRef78462 \" href=\"UTD.htm?29/6/29803\">",
"       table 1",
"      </a>",
"      ), as well as selected symptoms and findings that may occur in JHS, has been developed for establishing a diagnosis of JHS, once other causes of symptoms and more serious diseases associated with hypermobile joints have been excluded. The diagnosis is difficult to establish in children, who have greater joint laxity than adults. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diseases that have generalized joint laxity as a clinical feature are included in the differential diagnosis of JHS (",
"      <a class=\"graphic graphic_table graphicRef72776 \" href=\"UTD.htm?18/39/19067\">",
"       table 3",
"      </a>",
"      ). Most such disorders, including Marfan syndrome and most forms of Ehlers-Danlos syndrome (with the exception of the hypermobile type of Ehlers-Danlos syndrome), have one or more characteristic features that serve to distinguish them from JHS. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both nonpharmacologic and pharmacologic approaches may be useful in the management of joint hypermobility and JHS, including patient education, muscle strengthening, selected use of braces and orthoses, and use of nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Nonpharmacologic interventions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/1\">",
"      Grahame R. Joint hypermobility--clinical aspects. Proc R Soc Med 1971; 64:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/2\">",
"      Dequeker J. Benign familial hypermobility syndrome and Trendelenburg sign in a painting \"The Three Graces\" by Peter Paul Rubens (1577-1640). Ann Rheum Dis 2001; 60:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/3\">",
"      Grahame R, Hakim AJ. The rheumatological heritable disorders of connective tissue. Medicine &ndash; Rheumatology II 2009; 38:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/4\">",
"      Tinkle BT, Bird HA, Grahame R, et al. The lack of clinical distinction between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome). Am J Med Genet A 2009; 149A:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/5\">",
"      Juul-Kristensen B, R&oslash;gind H, Jensen DV, Remvig L. Inter-examiner reproducibility of tests and criteria for generalized joint hypermobility and benign joint hypermobility syndrome. Rheumatology (Oxford) 2007; 46:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/6\">",
"      Kirk JA, Ansell BM, Bywaters EG. The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility. Ann Rheum Dis 1967; 26:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/7\">",
"      el-Shahaly HA, el-Sherif AK. Is the benign joint hypermobility syndrome benign? Clin Rheumatol 1991; 10:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/8\">",
"      Thompson TR, Andrish JT, Bergfeld JA. A prospective study of preparticipation sports examinations of 2670 young athletes: method and results. Cleve Clin Q 1982; 49:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/9\">",
"      Al-Rawi ZS, Al-Aszawi AJ, Al-Chalabi T. Joint mobility among university students in Iraq. Br J Rheumatol 1985; 24:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/10\">",
"      Larsson LG, Baum J, Mudholkar GS, Srivastava DK. Hypermobility: prevalence and features in a Swedish population. Br J Rheumatol 1993; 32:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/11\">",
"      Grahame R, Bird H. Hypermobility in New Zealand. Rheumatology (Oxford) 2003; 42:491; author reply 491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/12\">",
"      Raskin RJ, Lawless OJ. Articular and soft tissue abnormalities in a \"normal\" population. J Rheumatol 1982; 9:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/13\">",
"      McCormack M, Briggs J, Hakim A, Grahame R. Joint laxity and the benign joint hypermobility syndrome in student and professional ballet dancers. J Rheumatol 2004; 31:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/14\">",
"      Dolan AL, Hart DJ, Doyle DV, et al. The relationship of joint hypermobility, bone mineral density, and osteoarthritis in the general population: the Chingford Study. J Rheumatol 2003; 30:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/15\">",
"      Hudson N, Starr MR, Esdaile JM, Fitzcharles MA. Diagnostic associations with hypermobility in rheumatology patients. Br J Rheumatol 1995; 34:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/16\">",
"      Hakim AJ, Cherkas LF, Grahame R, et al. The genetic epidemiology of joint hypermobility: a population study of female twins. Arthritis Rheum 2004; 50:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/17\">",
"      Finkelstein H. Joint hypotonia: with congenital and familial manifestations. New York Med J 1916; 104:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/18\">",
"      Schalkwijk J, Zweers MC, Steijlen PM, et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 2001; 345:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/19\">",
"      Zweers MC, Bristow J, Steijlen PM, et al. Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet 2003; 73:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/20\">",
"      Zweers MC, Hakim AJ, Grahame R, Schalkwijk J. Joint hypermobility syndromes: the pathophysiologic role of tenascin-X gene defects. Arthritis Rheum 2004; 50:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/21\">",
"      Bird HA, Tribe CR, Bacon PA. Joint hypermobility leading to osteoarthrosis and chondrocalcinosis. Ann Rheum Dis 1978; 37:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/22\">",
"      Brown AR, Rose BS. Familial precocious polyarticular osteoarthrosis of chondrodysplastic type. N Z Med J 1966; 65:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/23\">",
"      Kraus VB, Li YJ, Martin ER, et al. Articular hypermobility is a protective factor for hand osteoarthritis. Arthritis Rheum 2004; 50:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/24\">",
"      Chen HC, Shah SH, Li YJ, et al. Inverse association of general joint hypermobility with hand and knee osteoarthritis and serum cartilage oligomeric matrix protein levels. Arthritis Rheum 2008; 58:3854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/25\">",
"      Mishra MB, Ryan P, Atkinson P, et al. Extra-articular features of benign joint hypermobility syndrome. Br J Rheumatol 1996; 35:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/26\">",
"      Grahame R, Edwards JC, Pitcher D, et al. A clinical and echocardiographic study of patients with the hypermobility syndrome. Ann Rheum Dis 1981; 40:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/27\">",
"      Yazici M, Ataoglu S, Makarc S, et al. The relationship between echocardiographic features of mitral valve and elastic properties of aortic wall and Beighton hypermobility score in patients with mitral valve prolapse. Jpn Heart J 2004; 45:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/28\">",
"      Jessee EF, Owen DS Jr, Sagar KB. The benign hypermobile joint syndrome. Arthritis Rheum 1980; 23:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/29\">",
"      Walker BA, Beighton PH, Murdoch JL. The marfanoid hypermobility syndrome. Ann Intern Med 1969; 71:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/30\">",
"      GOODMAN RM, WOOLEY CF, FRAZIER RL, COVAULT L. EHLERS-DANLOS SYNDROME OCCURRING TOGETHER WITH THE MARFAN SYNDROME. REPORT OF A CASE WITH OTHER FAMILY MEMBERS AFFECTED. N Engl J Med 1965; 273:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/31\">",
"      Howes RG, Isdale IC. The loose back: an unrecognized syndrome. Rheumatol Phys Med 1971; 11:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/32\">",
"      Larsson LG, Mudholkar GS, Baum J, Srivastava DK. Benefits and liabilities of hypermobility in the back pain disorders of industrial workers. J Intern Med 1995; 238:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/33\">",
"      Bridges AJ, Smith E, Reid J. Joint hypermobility in adults referred to rheumatology clinics. Ann Rheum Dis 1992; 51:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/34\">",
"      Ofluoglu D, Gunduz OH, Kul-Panza E, Guven Z. Hypermobility in women with fibromyalgia syndrome. Clin Rheumatol 2006; 25:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/35\">",
"      Hirsch C, John MT, Stang A. Association between generalized joint hypermobility and signs and diagnoses of temporomandibular disorders. Eur J Oral Sci 2008; 116:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/36\">",
"      De Coster PJ, Van den Berghe LI, Martens LC. Generalized joint hypermobility and temporomandibular disorders: inherited connective tissue disease as a model with maximum expression. J Orofac Pain 2005; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/37\">",
"      Aktas I, Ofluoglu D, Albay T. The relationship between benign joint hypermobility syndrome and carpal tunnel syndrome. Clin Rheumatol 2008; 27:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/38\">",
"      Ercolani M, Galvani M, Franchini C, et al. Benign joint hypermobility syndrome: psychological features and psychopathological symptoms in a sample pain-free at evaluation1. Percept Mot Skills 2008; 107:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/39\">",
"      Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003; 115:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/40\">",
"      Grahame R, Hakim AJ. Hypermobility. Curr Opin Rheumatol 2008; 20:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/41\">",
"      Bulbena A, Dur&oacute; JC, Porta M, et al. Anxiety disorders in the joint hypermobility syndrome. Psychiatry Res 1993; 46:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/42\">",
"      Mart&iacute;n-Santos R, Bulbena A, Porta M, et al. Association between joint hypermobility syndrome and panic disorder. Am J Psychiatry 1998; 155:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/43\">",
"      Finsterbush A, Pogrund H. The hypermobility syndrome. Musculoskeletal complaints in 100 consecutive cases of generalized joint hypermobility. Clin Orthop Relat Res 1982; :124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/44\">",
"      Wolfe F. Clinical, laboratory, and radiographic assessments. Curr Opin Rheumatol 1993; 5:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/45\">",
"      Grahame R, Bird HA, Child A. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol 2000; 27:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Beighton PB, Grahame R, Bird HA. Hypermobility of Joints, 2nd, Springer, New York 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/47\">",
"      Fairbank JC, Pynsent PB, Phillips H. Quantitative measurements of joint mobility in adolescents. Ann Rheum Dis 1984; 43:288.",
"     </a>",
"    </li>",
"    <li>",
"     Gedalia A, Person DA, Giannini EH, Brewer EJ. Joint hypermobility in juvenile episodic arthritis/arthralgia. Paper presented to the Central Region Interim Meeting, American Rheumatism Association, Chicago 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/49\">",
"      Adib N, Davies K, Grahame R, et al. Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? Rheumatology (Oxford) 2005; 44:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/50\">",
"      Viswanathan V, Khubchandani RP. Joint hypermobility and growing pains in school children. Clin Exp Rheumatol 2008; 26:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/51\">",
"      Remvig L, Duhn PH, Ullman S, et al. Skin extensibility and consistency in patients with Ehlers-Danlos syndrome and benign joint hypermobility syndrome. Scand J Rheumatol 2009; 38:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/52\">",
"      Heidbreder AE, Ringelstein EB, Dittrich R, et al. Assessment of skin extensibility and joint hypermobility in patients with spontaneous cervical artery dissection and Ehlers-Danlos syndrome. J Clin Neurosci 2008; 15:650.",
"     </a>",
"    </li>",
"    <li>",
"     www.ncbi.nlm.nih.gov/omim/ (Accessed on February 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/54\">",
"      Sheon RP, Kirsner AB, Farber SJ, Finkel RI. The hypermobility syndrome. Postgrad Med 1982; 71:199.",
"     </a>",
"    </li>",
"    <li>",
"     Hakim AJ, Keer R, Grahame R. Hypermobility, Fibromyalgia, and Chronic Pain, 1st, Churchill Livingston, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2953/abstract/56\">",
"      Beighton PH, Horan FT. Dominant inheritance in familial generalised articular hypermobility. J Bone Joint Surg Br 1970; 52:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5591 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2953=[""].join("\n");
var outline_f2_56_2953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1229030\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Joint hypermobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Beighton hypermobility score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Generalized joint hypermobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Joint hypermobility syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevalence of generalized hypermobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevalence of JHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Musculoskeletal complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Extraarticular associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other manifestations of lax connective tissue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ehlers-Danlos syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Patient education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Braces and orthoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Muscle strengthening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1229030\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5591\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5591|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/31/33278\" title=\"picture 1A\">",
"      Wrist hypermobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/2/39981\" title=\"picture 1B\">",
"      Elbow hypermobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/7/35965\" title=\"picture 1C\">",
"      Knee hypermobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/59/1983\" title=\"picture 1D\">",
"      Spinal hypermobility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5591|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/6/29803\" title=\"table 1\">",
"      Beighton Score for joint laxity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/25/33179\" title=\"table 2\">",
"      Diagnostic criteria for BJHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/39/19067\" title=\"table 3\">",
"      Joint laxity disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=related_link\">",
"      Growing pains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=related_link\">",
"      Initial treatment of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=related_link\">",
"      Joint protection program for the lower limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37508?source=related_link\">",
"      Joint protection program for the upper limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/60/15298?source=related_link\">",
"      Patient information: Ehlers-Danlos syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_56_2954="Treatment of relapsed and refractory testicular germ cell tumors";
var content_f2_56_2954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed and refractory testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/56/2954/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2954/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2954/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/56/2954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2954/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/56/2954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/56/2954/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/56/2954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular germ cell tumors (GCTs) have become one of the most curable solid neoplasms because of remarkable treatment advances that began in the late 1970s.",
"   </p>",
"   <p>",
"    Prior to the development of effective chemotherapy regimens, the five-year survival rate among men with testicular GCTs was 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/1\">",
"     1",
"    </a>",
"    ]. Currently, the five-year survival rate is over 95 percent for both seminomas and nonseminomatous germ cell tumors (NSGCTs) and there about 350 deaths annually from testicular cancer in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based combination chemotherapy can cure patients with disseminated GCTs, even in the context of widespread visceral metastases, highly elevated serum tumor markers, and other adverse prognostic features. In contrast to the excellent outcomes for men with good-risk advanced testicular GCTs (91 percent five-year survival), up to 50 percent of men who have features of intermediate- or poor-risk disease require salvage therapy for relapsed disease following first-line chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef61906 \" href=\"UTD.htm?41/46/42732\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=see_link\">",
"     \"Risk stratification of metastatic testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy in patients with extragonadal (mediastinal, retroperitoneal) GCTs is generally based upon the experience in men with testicular GCTs and these patients are often included in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of men who progress during chemotherapy or relapse following treatment for GCTs will be reviewed here. The use of chemotherapy to treat patients with advanced chemotherapy-na&iuml;ve disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of relapsed disease is made by an increase in serum tumor markers or evidence of disease progression on radiographic studies. Most cases of relapsed testicular GCTs following chemotherapy are discovered during posttreatment surveillance for men who have completed therapy for testicular cancer. This includes men with a partial or complete response to treatment, in whom serum tumor markers had been normal or normalized. Such surveillance consists of periodic history and physical examinations, serum tumor marker assessments, and radiographic studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=see_link\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following initial treatment, periodic surveillance of the serum concentrations of human chorionic gonadotropin (hCG) and alpha fetoprotein (AFP) is the most sensitive means of detecting relapse. An increase in serum tumor markers represents the first evidence of disease in over one-half of patients with NSGCT who relapse, including some whose marker values were normal at the time of their initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. While elevated serum tumor markers are unusual among men with relapsing chemotherapy-naive pure seminomas, those who relapse following chemotherapy usually have elevated levels of serum beta-HCG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lactate dehydrogenase (LDH) when relapse is discovered [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H17#H17\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'Monitoring response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern of spread for testicular GCTs is very predictable; men with clinical stage I disease rarely develop mediastinal metastases without also developing retroperitoneal adenopathy. For men with normal serum tumor markers and relapse only in the mediastinal and hilar nodes or other atypical relapse patterns, biopsy should be considered to exclude other diagnoses. In particular, sarcoidosis has an increased incidence in men with testicular GCTs, particularly seminoma. However, there are case reports of men with simultaneous noncaseating granulomas and relapsed testis cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. Thus, careful clinical decision making is essential if a biopsy shows sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14685200\">",
"    <span class=\"h1\">",
"     CATEGORIES OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for men with relapsed GCTs depends upon the initial treatment and response to prior therapy, the location and timing of the relapse, and tumor histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14685207\">",
"    <span class=\"h2\">",
"     Chemotherapy-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of relapsing patients whose initial treatment did not include chemotherapy depends upon histology:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95689220\">",
"    <span class=\"h3\">",
"     Nonseminomatous GCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with NSGCTs who relapse while undergoing surveillance after orchiectomy for a stage I tumor can almost always be salvaged. These men are generally treated with standard first-line",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy, although those with clinical stage IIA disease at relapse and normal serum tumor markers may undergo retroperitoneal lymph node dissection (RPLND). Surgical resection of residual masses following chemotherapy is the standard of care for NSGCTs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgical management of advanced testicular germ cell tumors\", section on 'Nonseminomatous GCTs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95689235\">",
"    <span class=\"h3\">",
"     Seminomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men with seminoma who relapse after orchiectomy for stage I pure seminoma can be cured with radiation therapy while a few require standard first-line",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients who relapse after receiving radiation therapy (RT) can almost always be salvaged with standard first-line cisplatin-based chemotherapy. The role of surgical resection of residual masses following chemotherapy in patients with seminomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of stage II seminoma\", section on 'Bulky (stage IIB/IIC) seminoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14691107\">",
"    <span class=\"h2\">",
"     Relapse after initial chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who relapse after initial chemotherapy generally require additional chemotherapy. Both standard-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens and high-dose chemotherapy have been used in this setting. (See",
"    <a class=\"local\" href=\"#H109606309\">",
"     'Chemotherapy for initial relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14685235\">",
"    <span class=\"h2\">",
"     Relapse after salvage chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who relapse after initial salvage chemotherapy and those who progress during or immediately after their initial chemotherapy are considered to have platinum-refractory disease. Although the prognosis is generally poor, aggressive therapy can salvage some of these patients. (See",
"    <a class=\"local\" href=\"#H196220871\">",
"     'Platinum-refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95689263\">",
"    <span class=\"h2\">",
"     Growing teratoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of a teratoma must be considered in men with a history of NSGCT who have an enlarging mass and normal serum tumor markers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/19\">",
"     19",
"    </a>",
"    ]. Teratomas are relatively insensitive to chemotherapy and are usually managed with resection. Growing teratoma should be considered in late relapses and when a mass grows during chemotherapy despite declining serum tumor markers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical management of advanced testicular germ cell tumors\", section on 'Significance of teratoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because there is no way to know what histopathological elements are present within a mass prior to resection, growing masses are typically treated with chemotherapy to eradicate nonteratoma components. This is followed by resection of any residual disease. Good clinical judgment and experience are essential here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14685251\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who relapse after completing their chemotherapy can be subdivided according to various prognostic factors, including the response to the initial chemotherapy (primary refractory versus recurrence after a complete response), histology (seminoma versus NSGCT), and the site of the primary GCT (testicular versus extragonadal [retroperitoneal or mediastinal]). The heterogeneity of patients included in various studies based upon these and other factors makes it difficult to compare the relative efficacy of salvage strategies, which include standard-dose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -based chemotherapy and high-dose chemotherapy with hematopoietic stem cell rescue (HDT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Duration of initial remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to initial therapy (complete versus partial versus no response) and the duration of remission are important prognostic indicators. Progression of disease either during or within four weeks after completion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is considered cisplatin-refractory disease. These patients have a very poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H196220871\">",
"     'Platinum-refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Men with NSGCTs who relapse more than two years after their initial chemotherapy are often considered to have a poor prognosis, but cure rates of up to 68 percent have been reported in recent series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Aggressive surgical resection either as the primary treatment or following chemotherapy is strongly recommended for late relapsing NSGCTs because the best outcomes have been reported in men who have undergone resection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ]. Treatment with chemotherapy alone has yielded disappointing results in this setting. Late-relapsing seminomas have not been shown to differ from early relapsing seminomas and should generally be treated with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Late relapse'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"     \"Surgical management of advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Site of primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a relapse of a testicular GCT appear to have a better prognosis than those relapsing after chemotherapy for an extragonadal GCT. Relapsing mediastinal NSGCTs are successfully salvaged in only about 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with recurrent seminoma have better outcomes than those with NSGCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/18,30\">",
"     18,30",
"    </a>",
"    ]. Standard-dose salvage regimens result in long-term disease-free survival in approximately one-half of seminoma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This is also true for seminomas that relapse beyond two years. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Late relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109606624\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various other factors can also have a significant impact on outcome following treatment for relapsed disease. In a multicenter series of 1594 patients, patients were divided into five prognostic categories based upon response to first line therapy, serum tumor marker levels, and sites of metastatic involvement (bone, liver, brain), as well as the duration of initial remission, site of primary tumor, and histology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/31\">",
"     31",
"    </a>",
"    ]. Using all of these factors, three-year overall survival ranged from 65 to 89 percent for the lowest risk group to 4 to 27 percent for the highest risk group, depending upon therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109606309\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY FOR INITIAL RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy approaches used to treat a relapse following the initial chemotherapy regimen have included both standard-dose chemotherapy and high-dose chemotherapy with autologous hematopoietic stem cell rescue (HDT). Patients should be included in clinical trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Standard-dose chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most relapses occurring after primary chemotherapy are seen within the first two years. Results with salvage chemotherapy in this setting are less dramatic than with the initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based therapy. Most conventional-dose salvage regimens incorporate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and cisplatin combined with a third agent.",
"   </p>",
"   <p>",
"    The two most common standard-dose first-line salvage regimens combine three drugs and include both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TIP &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      175 - 250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      infused over 24 hours on day 1 followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      1500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for four days (days 2, 3, 4 and 5) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for four days (days 2, 3, 4, and 5) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VeIP &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       Vinblastine",
"      </a>",
"      0.11",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for two days,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      1200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results with standard-dose chemotherapy in this setting are illustrated by two large series using TIP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 46 men with relapsed testicular GCT were treated with the TIP regimen, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      support [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/32\">",
"       32",
"      </a>",
"      ]. Eligibility in this trial was limited to men with highly favorable prognostic factors: extragonadal primary tumors were excluded, no more than six cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy, and either a complete response or a partial radiographic response with normalization of serum tumor markers for more than six months in response to the initial regimen. In this highly selected patient population, a complete response was achieved in 63 percent with chemotherapy and 70 percent including subsequent resection of residual masses. Only 3 of the 32 complete responders relapsed with a mean duration of follow-up of 69 months.",
"     </li>",
"     <li>",
"      Less favorable results were noted in a second series of 51 men who received a modified TIP regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/34\">",
"       34",
"      </a>",
"      ]. Although 60 percent had a favorable response to chemotherapy, the failure-free survival rate at one year was only 36 percent. This study included both poor-risk and good-risk patients. When the analysis was limited to good-risk patients, one-year failure-free survival was 43 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those rare patients who did not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    as part of their first-line chemotherapy, the VIP regimen (etoposide 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    1.2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    all administered daily for five consecutive days every three weeks, is widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For relapsing patients who received VIP as first-line chemotherapy, optimal second-line chemotherapy is not well defined. Alternatives include high-dose chemotherapy, PVB (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ), and combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and cisplatin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These salvage regimens result in relapse-free survival in about 35 percent of men with recurrent GCT after first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/9,34\">",
"     9,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men with seminoma who relapsed following chemotherapy seem to fare better than those with NSGCTs. A review of 24 patients with recurrent seminoma treated at Indiana University (IU) with VeIP had a 54 percent long-term disease-free survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/10\">",
"     10",
"    </a>",
"    ], while 15 of 27 men (56 percent) with relapsed seminomas at Memorial Sloan Kettering (MSK) achieved durable remissions with either standard or high-dose chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     High-dose chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDT was initially used in the 1980s as a second- or third-line salvage approach. Although long-term disease-free survival was achieved in about 15 percent of cases, the rate of treatment-related mortality was approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H196221094\">",
"     'High-dose chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nonrandomized studies reported more favorable results when HDT was used as first-line salvage therapy for relapsed disease. In contemporary studies evaluating HDT as first-line salvage therapy, treatment-related mortality has been less than 5 percent, and long-term disease-free survival is between 40 and 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/30,31,41-44\">",
"     30,31,41-44",
"    </a>",
"    ]. However, the role of first-line salvage therapy using HDT has not been established in randomized clinical trials and this approach remains experimental. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Intermediate- and poor-risk advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analyses of data are complicated by the use of different HDT regimens and heterogeneous patient inclusion criteria. The conflicting data on the role of HDT are illustrated by following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No benefit from HDT was seen in a European trial (IT-94), in which 280 men were randomly assigned to four cycles of",
"      <span class=\"nowrap\">",
"       VIP/VeIP,",
"      </span>",
"      or three cycles of",
"      <span class=\"nowrap\">",
"       VIP/VeIP",
"      </span>",
"      followed by consolidation with one cycle of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (CEC) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/9\">",
"       9",
"      </a>",
"      ]. Consolidation with HDT failed to significantly improve the three-year event-free survival rate (42 versus 35 percent with four cycles of",
"      <span class=\"nowrap\">",
"       VIP/VeIP)",
"      </span>",
"      or overall survival (53 percent in each arm). However, the toxic death rate was higher in the HDT arm (7 versus 3 percent). However, only 73 percent of the patients assigned to the HDT arm actually received HDT.",
"     </li>",
"     <li>",
"      The most extensive observational data come from an international, multicenter series of 1594 patients with GCTs who relapsed after treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      regimen and were treated with either HDT or conventional-dose chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/45\">",
"       45",
"      </a>",
"      ]. There was marked heterogeneity in the HDT regimens used in the frequency with which HDT was used in different countries. Patients were classified into five prognostic categories, based upon histology, primary tumor site, response to first-line chemotherapy, progression-free interval, serum tumor markers, and sites of metastatic involvement. At a median follow-up of five years, the two-year progression-free survival rate for the entire series was significantly higher with HDT compared to conventional dose therapy (50 versus 28 percent, hazard ratio [HR] 0.44), as was the five-year overall survival rate (53 versus 41 percent, HR 0.65). Analyses of progression-free survival and overall survival rates based upon prognostic classification found similar results in all groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences between these two reports may reflect various biases inherent in an observational study or may reflect limitations in the specific regimen used in the European IT-94 trial, which included only one cycle of HDT given after three cycles of conventional dose chemotherapy. The administration of a second-cycle of high-dose chemotherapy may have contributed to improved outcomes in some series. However, a German randomized controlled trial found no difference in three-year survival (46 versus 48 percent) when it compared one cycle of standard-dose VIP chemotherapy followed by three cycles of high dose EC chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) to three cycles of standard-dose VIP followed by one cycle of high-dose CEC chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although HDT has been accepted by many as an appropriate first-line salvage treatment for testicular NSGCTs, many HDT studies excluded patients with poor prognostic features. Consequently, part of the apparent benefit from HDT compared to standard-dose salvage chemotherapy may be attributable to patient selection.",
"   </p>",
"   <p>",
"    Additional randomized trials comparing conventional-dose salvage chemotherapy (eg, VeIP or TIP) to HDT as first-line salvage treatment are needed. Because a single course of HDT offered no advantage in the IT-94 trial, the central unanswered question is whether two or more courses of high-dose chemotherapy are superior to four cycles of standard-dose salvage chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196220871\">",
"    <span class=\"h1\">",
"     PLATINUM-REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with GCTs in second or subsequent relapse (ie, who have failed on an initial salvage regimen) and those who progress during or immediately after their initial platinum-based chemotherapy regimen are considered to have platinum-refractory disease. These patients have a poorer prognosis than those treated for with salvage chemotherapy for their initial relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/30,40,43,47\">",
"     30,40,43,47",
"    </a>",
"    ]. However, salvage is still possible in some cases. These patients should be referred to a cancer center with expertise in GCTs. (See",
"    <a class=\"local\" href=\"#H109606309\">",
"     'Chemotherapy for initial relapse'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196221094\">",
"    <span class=\"h2\">",
"     High-dose chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who were managed with conventional-dose therapy in their initial salvage regimen, high-dose chemotherapy with autologous stem cell rescue (HDT) is the preferred option. In the Indiana University experience in a series of 184 consecutive patients, 22 of 49 patients (41 percent) treated with third-line or later HDT and 18 of 40",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -refractory patients (45 percent) remained disease-free after treatment with two cycles of HDT, compared with 98 of 144 cisplatin-sensitive patients (68 percent) who were treated with HDT for their initial relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/30\">",
"     30",
"    </a>",
"    ]. Median follow-up for the entire series was 48 months, and 104 of 116 patients who were continuously disease-free following HDT had been observed for more than two years.",
"   </p>",
"   <p>",
"    The choice of agents for HDT varies among institutions. In the United States and some European centers, high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (EC) is commonly administered with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/41,48-50\">",
"     41,48-50",
"    </a>",
"    ]. High-dose regimens that incorporate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    have also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. There are no randomized trials that compare these more complex regimens to EC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196221101\">",
"    <span class=\"h2\">",
"     Newer agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens incorporating new agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    show some promise in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/36-39,56-58\">",
"     36-39,56-58",
"    </a>",
"    ]. Despite the poor prognosis for most patients, some individuals achieve durable complete remissions.",
"   </p>",
"   <p>",
"    Examples of such experimental regimens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II study from the Eastern Cooperative Oncology Group (ECOG), 28 patients with chemotherapy-refractory GCTs were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/39\">",
"       39",
"      </a>",
"      ]. Six patients (21 percent) responded and two of the three complete responders (7 percent of the total) were continuously disease-free at 15 and 25 months, respectively. In a partially overlapping retrospective series of 32 patients from IU, four (13 percent) achieved durable complete remission with chemotherapy alone (durations 20+ to 57+ months), and a fifth did so with surgery to resect residual disease (duration 63+ months) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two phase II trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      enrolling a combined total of 59 men have been published. The overall response rates were 32 and 46 percent, respectively, and 11 to 14 percent were in remission at the time of reporting [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/38,58\">",
"       38,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase II Italian study in 22 patients who had received either at least two prior regimens (n=20) or prior high-dose chemotherapy (n=2) reported that the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      resulted in a five year overall survival of 18 percent. The median follow-up in this study was over six years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/35\">",
"       35",
"      </a>",
"      ]. All survivors had surgery following chemotherapy to resect residual masses.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      was evaluated in a phase II study, in which 21 of 41 patients (51 percent) had an objective response, including two (5 percent) with a complete response [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/36\">",
"       36",
"      </a>",
"      ]. Additional patients achieved a complete response with post-chemotherapy resection of residual masses and 17 percent of patients were disease-free at a median follow-up of only five months.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       Epirubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      was evaluated in a phase II study of 30 men with refractory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/57\">",
"       57",
"      </a>",
"      ]. Nine patients were rendered disease-free, in most instances with surgery or radiation to treat post-chemotherapy residual masses. Seven men remained continuously disease-free 25+ to 48+ months after chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LATE RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large majority of relapses occur within the first two years following the completion of first-line chemotherapy for advanced testicular GCT. Relapses that occur after two years are considered late relapses.",
"   </p>",
"   <p>",
"    Estimates of the frequency of late relapse have been derived from reports of single center experience. A pooled analysis of publications between 1989 and 2006 that included 3700 men with NSGCTs and 2200 with seminomas found the incidence of late relapse to be 3.2 and 1.4 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/59\">",
"     59",
"    </a>",
"    ]. In the same report, a pooled analysis of 521 late-relapsing patients indicated that late relapses in NSGCTs are most common in the retroperitoneum, occurring in approximately one-half of cases overall. The lungs (17 percent), mediastinum (9 percent), neck and supraclavicular region (6.5 percent) and pelvis (4.4 percent) accounted for most of the remaining relapses.",
"   </p>",
"   <p>",
"    Seminomas differed from NSGCTs in that nodal metastases were much more frequent. The retroperitoneum accounted for most relapses (55 percent) followed by the mediastinum (27 percent), neck and supraclavicular region (15 percent), lungs (3.2 percent) and pelvis (1.6 percent). Only about 5 percent of late seminoma relapses occurred in other locations, such as liver or bone, compared to nearly 12 percent of NSGCTs.",
"   </p>",
"   <p>",
"    Serum tumor markers are useful in detecting late relapses: about 50 percent have elevated AFP and about 25 percent have elevated HCG at the time of late relapse.",
"   </p>",
"   <p>",
"    Late-relapsing NSGCTs tend to be slow growing and relatively chemotherapy resistant compared to early relapsing disease or GCTs that present with advanced disease. Long-term survivors tend to be those with localized recurrences that are cured by surgery with or without chemotherapy.",
"   </p>",
"   <p>",
"    The outcomes following treatment are illustrated by several large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from IU analyzed outcomes following treatment for late relapses in 83 men (80 NSGCT, 3 seminomas) who had been relapse-free for at least two years following treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/25\">",
"       25",
"      </a>",
"      ]. Two received no therapy, and 69 of the 81 treated patients were rendered free of disease by treatment, including 43 of the 49 who underwent surgery. With a median follow-up of 25 months, 38 (47 percent) were continuously free of disease following salvage therapy. Of the 32 patients treated with chemotherapy alone, only five remained continuously disease-free.",
"     </li>",
"     <li>",
"      In a German series of 122 men with late relapse after initial therapy, 42 of 48 seminomas (88 percent) but only 35 of 72 patients with NSGCT (48 percent) were alive and without evidence of disease at last follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/23\">",
"       23",
"      </a>",
"      ]. For patients with NSGCT, the highest cure rate (50 percent) was achieved among those who underwent surgery as a component of their treatment. For seminomas, chemotherapy alone was effective in over one-half of cases.",
"     </li>",
"     <li>",
"      In a series of 75 patients (70 with NSGCTs) from Memorial Sloan-Kettering Cancer Center, the five-year cancer-specific survival (CSS) was 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/21\">",
"       21",
"      </a>",
"      ]. The outcome was better in those underwent complete surgical resection at the time of late relapse (five-year CSS 79 versus 36 percent in those without complete resection). Patients who had not been treated previously with chemotherapy also had a better outcome (five-year CSS 93 versus 49 percent). In a multivariable analysis, unifocal disease and the absence of symptoms were associated with longer CSS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lifetime follow-up is necessary for men who achieve disease-free status after a late relapse because of the high frequency of second relapses. In a follow-up series based upon 37 men with late relapse, 9 of the 19 who achieved no evidence of disease (NED) status relapsed a second time, including five with a second late relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these and other observations, the following generalizations can be made about late relapses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than one-half of late relapses occur more than five years after completing chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Risk factors for late relapse include poor-prognosis disease at initial diagnosis, bulky retroperitoneal disease, and prior early relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most late relapses are malignant, although 10 to 20 percent are teratomas. (See",
"      <a class=\"local\" href=\"#H95689263\">",
"       'Growing teratoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Between 30 and 50 percent of late relapses are associated with normal serum tumor markers. Therefore, long-term annual radiographic surveillance should be considered for all patients with a history of GCTs [",
"      <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/25,26,60,62\">",
"       25,26,60,62",
"      </a>",
"      ]. However, the use of long-term radiologic surveillance for all patients with GCTs is controversial; some experts believe that surveillance should be tailored to the individual patient's risk. Ideally, the benefit of surveillance should be weighed against the risk of second malignancies from the radiation exposure.",
"     </li>",
"     <li>",
"      An aggressive surgical approach should be adopted in patients who have late relapse of NSGCTs, since resection appears to be crucial to achieving long-term survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"       \"Surgical management of advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late-relapsing seminomas should be treated in the same manner as early-relapsing seminomas. (See",
"      <a class=\"local\" href=\"#H95689235\">",
"       'Seminomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     BRAIN METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) metastases occur in about 1 percent of men with disseminated germ cell cancer at the time of diagnosis and between 0.4 and 4 percent subsequently develop brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Brain metastases almost always occur in the setting of concurrent or prior disseminated disease and are associated with a poor prognosis. Brain metastases are particularly common with choriocarcinoma, and these metastases have a tendency to bleed both spontaneously and during treatment with chemotherapy.",
"   </p>",
"   <p>",
"    For prognostic purposes, patients with brain metastases can be divided into three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who have brain metastases detected prior to first-line chemotherapy",
"     </li>",
"     <li>",
"      Those who relapse only in the brain after achieving a complete response to chemotherapy and, if indicated, subsequent surgery",
"     </li>",
"     <li>",
"      Those who develop brain metastases after failing to achieve a complete response to chemotherapy and surgery or who develop both brain and extracranial metastases during or after chemotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cancer-specific survival figures range from 43 to 86 percent for group 1, 39 to 44 percent for group 2, and 2 to 26 percent for group 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/67-73\">",
"     67-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes and influence of other prognostic factors are illustrated by a pooled analysis of 139 European patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 56 men with at least one brain metastasis at diagnosis, two-year survival was 76 versus 38 percent for those with single versus multiple brain tumors. Superior survival was associated with the absence of liver and bone metastases and with the performance of neurosurgery to resect the tumors but not with radiation therapy or intensified chemotherapy regimens (as compared to BEP).",
"     </li>",
"     <li>",
"      Among the 83 patients who developed brain metastases during or after chemotherapy, two-year survival was 27 versus 1 percent for those with single versus multiple lesions. The five-year survival was 39 percent for those with brain-only relapses compared to 2 percent for those with brain plus extracranial metastases. Survival among patients relapsing during or after chemotherapy was zero in those patients who had a serum HCG greater than 5000 international",
"      <span class=\"nowrap\">",
"       units/L,",
"      </span>",
"      AFP greater than 500",
"      <span class=\"nowrap\">",
"       ng/ml,",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a prior postchemotherapy relapse. Superior survival in these 83 men was associated with the inclusion of radiation therapy and the absence of both extracranial relapses and prior postchemotherapy relapses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal treatment approach for patients with brain metastases is uncertain and there are no prospective data that adequately address this issue. Systemic chemotherapy, various RT modalities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical excision may all be useful in selected circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients with brain metastases, systemic chemotherapy is used initially because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    penetrate the brain in the presence of metastases and because controlling disease systemic disease is an important priority. If repeat neuroimaging documents a complete response, we generally prefer careful observation without further treatment. If there is a limited amount of residual tumor following chemotherapy, surgical excision",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal RT is used to eradicate the residual disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link&amp;anchor=H2#H2\">",
"     \"Systemic therapy for brain metastases\", section on 'Factors affecting responsiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with brain metastases need to be treated in a center with tertiary neurosurgical support as well as radiation oncology and medical oncology expertise in treating GCTs with brain metastases. The use of chemotherapy for initial management risks central nervous system hemorrhage during the cytopenia associated with chemotherapy.",
"   </p>",
"   <p>",
"    When possible, whole brain RT is avoided because of concerns about the late complications of cranial irradiation. Whole brain RT may be indicated for patients with more extensive residual disease or those with brain metastases that do not respond to systemic chemotherapy. Although whole brain RT has been combined with concurrent chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], this approach may increase the risk of severe, symptomatic white matter changes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/56/2954/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"     \"Complications of cranial irradiation\", section on 'Late reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for men with relapsed germ cell tumors (GCTs) depends upon the patient's previous treatment and response to therapy, the location and timing of the relapse, and tumor histology. Aggressive therapy is warranted for both the initial presentation with metastatic disease and for subsequent relapses, since cure is possible in a substantial number of patients. (See",
"    <a class=\"local\" href=\"#H109606309\">",
"     'Chemotherapy for initial relapse'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H196220871\">",
"     'Platinum-refractory disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men with relapsed or refractory testicular GCTs should be referred to a cancer center with multidisciplinary expertise, and patients should be offered the opportunity to participate in clinical studies whenever possible.",
"     </li>",
"     <li>",
"      For men who relapse while undergoing surveillance for a stage I testicular GCT or for men with seminoma who relapse after receiving either radiation therapy or single-agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      chemotherapy, reasonable options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy or retroperitoneal lymph node dissection (RPLND) plus, where appropriate, adjuvant chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"       \"Surgical management of advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men who relapse within two years after an initial complete response to chemotherapy, we recommend systemic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For men with nonseminomatous GCTs, surgery should be performed if needed after chemotherapy to remove any residual masses and achieve a radiographic disease-free status. (See",
"      <a class=\"local\" href=\"#H109606309\">",
"       'Chemotherapy for initial relapse'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"       \"Surgical management of advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest standard-dose chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The primary options are either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (VeIP) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , ifosfamide plus cisplatin (TIP). For patients who have not previously received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , our preferred regimen is etoposide, ifosfamide, and cisplatin (VIP). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Standard-dose chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two or more cycles of high-dose chemotherapy with autologous hematopoietic stem cell rescue (HDT) is an alternative in centers with appropriate expertise. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'High-dose chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with platinum-refractory disease who progress during or within four weeks after their initial chemotherapy, we recommend HDT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H196220871\">",
"       'Platinum-refractory disease'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Late relapses (ie, after two years) are uncommon. Late-relapsing nonseminomatous GCTs tend to be slow growing and relatively chemotherapy resistant compared to early relapsing disease or GCTs that present with advanced disease. Late relapsing seminomas often contain nonseminomatous components at relapse and late relapsing nonseminomas may relapse as pure teratomas; biopsy of late relapses is thus important in most cases. We recommend an aggressive surgical approach in addition to systemic therapy in late-relapsing patients, since resection appears to be crucial to achieving long-term survival (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For men with pure seminomas, late and early relapses are treated in a similar manner with standard-dose or high-dose chemotherapy, but biopsy to confirm the histopathology is important. Patients who have had a late relapse are at high risk of a second late relapse and are good candidates for long-term surveillance. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Late relapse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H95689263\">",
"       'Growing teratoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"       \"Surgical management of advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain metastases usually present in conjunction with other systematic metastases but metastatic germ cell tumors that have been previously treated with chemotherapy sometimes have relapses isolated to the brain. Most patients who have brain metastasis at the time of diagnosis have a reasonable chance of being cured, as do those with brain-only relapses, but patients who relapse in the brain and other locations after chemotherapy are only rarely cured. Systemic chemotherapy is usually preferred for initial treatment, although resection of residual lesions is recommended when feasible, and RT may also have a role. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Brain metastases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"       \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/1\">",
"      Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute, Bethesda, MD, 2004 file://seer.cancer.gov/csr/1975_2007/index.html (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/3\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/4\">",
"      Culine S, Kramar A, Th&eacute;odore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008; 26:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/5\">",
"      Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/6\">",
"      Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003; 97:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/7\">",
"      de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/8\">",
"      Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/9\">",
"      Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/10\">",
"      Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 1997; 15:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/11\">",
"      Vuky J, Tickoo SK, Sheinfeld J, et al. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002; 20:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/12\">",
"      Foss&aring; A, Foss&aring; SD. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma. Br J Urol 1989; 63:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/13\">",
"      Rayson D, Burch PA, Richardson RL. Sarcoidosis and testicular carcinoma. Cancer 1998; 83:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/14\">",
"      Foss&aring; SD, Abeler V, Marton PF, et al. Sarcoid reaction of hilar and paratracheal lymph nodes in patients treated for testicular cancer. Cancer 1985; 56:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/15\">",
"      Heffner JE, Milam MG. Sarcoid-like hilar and mediastinal lymphadenopathy in a patient with metastatic testicular cancer. Cancer 1987; 60:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/16\">",
"      Tjan-Heijnen VC, Vlasveld LT, Pernet FP, et al. Coincidence of seminoma and sarcoidosis: a myth or fact? Ann Oncol 1998; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/17\">",
"      Leatham EW, Eeles R, Sheppard M, et al. The association of germ cell tumours of the testis with sarcoid-like processes. Clin Oncol (R Coll Radiol) 1992; 4:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/18\">",
"      Warde P, Gospodarowicz M. Evolving concepts in stage I seminoma. BJU Int 2009; 104:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/19\">",
"      Andr&eacute; F, Fizazi K, Culine S, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000; 36:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/20\">",
"      Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/21\">",
"      Sharp DS, Carver BS, Eggener SE, et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 2008; 26:5524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/22\">",
"      Oldenburg J, Alfsen GC, Waehre H, Foss&aring; SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 2006; 94:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/23\">",
"      Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 2005; 173:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/24\">",
"      Oldenburg J, Foss&aring; SD. Late relapse of nonseminomatous germ cell tumours. BJU Int 2009; 104:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/25\">",
"      George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/26\">",
"      Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 2005; 23:6999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/27\">",
"      Broun ER, Nichols CR, Kneebone P, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/28\">",
"      Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/29\">",
"      Hartmann JT, Einhorn L, Nichols CR, et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 2001; 19:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/30\">",
"      Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357:340.",
"     </a>",
"    </li>",
"    <li>",
"     Lorch A, Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors (abstract 4513). J Clin Oncol 2010; 28:345s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/32\">",
"      Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23:6549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/33\">",
"      Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/34\">",
"      Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005; 93:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/35\">",
"      Nicolai N, Necchi A, Gianni L, et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int 2009; 104:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/36\">",
"      Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008; 19:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/37\">",
"      Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007; 25:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/38\">",
"      Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/39\">",
"      Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002; 20:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/40\">",
"      Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/41\">",
"      Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18:3346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/42\">",
"      Bokemeyer C, Harstrick A, Beyer J, et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol 1998; 25:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/43\">",
"      Beyer J, Kingreen D, Krause M, et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 1997; 79:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/44\">",
"      Beyer J, Stenning S, Gerl A, et al. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 2002; 13:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/45\">",
"      Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/46\">",
"      Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007; 25:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/47\">",
"      Rick O, Beyer J, Kingreen D, et al. High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer 1998; 34:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/48\">",
"      Broun ER, Nichols CR, Gize G, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 1997; 79:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/49\">",
"      Margolin K, Doroshow JH, Ahn C, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996; 14:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/50\">",
"      Nichols C, Maziarz R. High dose chemotherapy--results of American studies. Int J Cancer 1999; 83:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/51\">",
"      Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/52\">",
"      Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/53\">",
"      Rick O, Siegert W, Beyer J. High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany. Int J Cancer 1999; 83:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/54\">",
"      Rodenhuis S, de Wit R, de Mulder PH, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999; 10:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/55\">",
"      Margolin KA, Doroshow JH, Frankel P, et al. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biol Blood Marrow Transplant 2005; 11:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/56\">",
"      Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/57\">",
"      Bedano PM, Brames MJ, Williams SD, et al. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. J Clin Oncol 2006; 24:5403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/58\">",
"      Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004; 15:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/59\">",
"      Oldenburg J, Martin JM, Foss&aring; SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 2006; 24:5503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/60\">",
"      Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997; 8:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/61\">",
"      Gerl A, Hentrich M, Weber N, et al. Clinical characteristics and outcome of late relapse after cisplatin-based chemotherapy of germ cell tumor: An update (abstract). Proc Am Soc Clin Oncol 2004; 23:387a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/62\">",
"      Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol 1995; 13:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/63\">",
"      International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/64\">",
"      Foss&aring; SD, Bokemeyer C, Gerl A, et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 1999; 85:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/65\">",
"      Raina V, Singh SP, Kamble N, et al. Brain metastasis as the site of relapse in germ cell tumor of testis. Cancer 1993; 72:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/66\">",
"      Raghavan D, Mackintosh JF, Fox RM, et al. Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment. Br J Urol 1987; 60:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/67\">",
"      Doyle DM, Einhorn LH. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys 2008; 70:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/68\">",
"      Gremmer R, Schr&ouml;der ML, Ten Huinink WW, et al. Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. J Neurooncol 2008; 90:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/69\">",
"      Hartmann JT, Bamberg M, Albers P, et al. Multidisciplinary treatment and prognosis of patients (pts) with central nervous system metastases (CNS) from testicular germ cell tumor (GCT) origin. Proc Am Soc Clin Oncol 2003; 22:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/70\">",
"      Kollmannsberger C, Nichols C, Bamberg M, et al. First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 2000; 11:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/71\">",
"      Nonomura N, Nagahara A, Oka D, et al. Brain metastases from testicular germ cell tumors: a retrospective analysis. Int J Urol 2009; 16:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/72\">",
"      Salvati M, Piccirilli M, Raco A, et al. Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment. Neurosurg Rev 2006; 29:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/73\">",
"      Spears WT, Morphis JG 2nd, Lester SG, et al. Brain metastases and testicular tumors: long-term survival. Int J Radiat Oncol Biol Phys 1992; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/56/2954/abstract/74\">",
"      Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 1997; 15:1449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2999 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2954=[""].join("\n");
var outline_f2_56_2954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14685200\">",
"      CATEGORIES OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14685207\">",
"      Chemotherapy-naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95689220\">",
"      - Nonseminomatous GCTs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95689235\">",
"      - Seminomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14691107\">",
"      Relapse after initial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14685235\">",
"      Relapse after salvage chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95689263\">",
"      Growing teratoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14685251\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Duration of initial remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Site of primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109606624\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109606309\">",
"      CHEMOTHERAPY FOR INITIAL RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Standard-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      High-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196220871\">",
"      PLATINUM-REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196221094\">",
"      High-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196221101\">",
"      Newer agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LATE RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      BRAIN METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2999\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2999|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/46/42732\" title=\"table 1\">",
"      Risk strat system advancted TGCTs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=related_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=related_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_56_2955="Unintended loss rate after MPR by finishing number";
var content_f2_56_2955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Unintended loss rate after MPR by finishing number",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finishing number (n)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss rate (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1 (118)",
"       </td>",
"       <td class=\"centered\">",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2 (864)",
"       </td>",
"       <td class=\"centered\">",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3 (18)",
"       </td>",
"       <td class=\"centered\">",
"        16.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stone J, Eddleman K, Lynch L, Berkowitz RL. A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 2002; 187:1163. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2955=[""].join("\n");
var outline_f2_56_2955=null;
var title_f2_56_2956="ACC AHA serial assessment HF";
var content_f2_56_2956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Serial clinical assessment of patients with heart failure (HF)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following serial clinical assessments should be performed at each visit in patients with HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; The ability to perform routine and desired activities of daily living.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Volume status and weight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Careful history of current use of alcohol, tobacco, illicit drugs, \"alternative therapies,\" and chemotherapy drugs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Diet and sodium intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following serial clinical assessment in patients with HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Repeat measurements of left ventricular ejection fraction and the severity of structural remodeling in patients who have had a change in clinical status or who have experienced or recovered from a clinical event or received treatment that might have had a significant effect on cardiac function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following serial clinical assessment of patients with HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Serial measurements of serum B-type natriuretic peptide (BNP) to guide therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2956=[""].join("\n");
var outline_f2_56_2956=null;
var title_f2_56_2957="Causes edema childhood";
var content_f2_56_2957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of edema in childhood",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Generalized edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Increased capillary hydrostatic pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Increased plasma volume from sodium and water retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        (Localization can be seen in some cardiac disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Primary renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Acute glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Renal failure (acute/chronic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Drug induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Vasodilators (eg, minoxodil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Dihydropyridine calcium channel blockers (eg, nifedepine and amlodipine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Venous obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Hepatic cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Decreased capillary oncotic pressure (Hypoalbuminemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein losing enteropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein malnutrition (kwashiorkor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Increased capillary permeability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Localized edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Increased capillary hydrostatic pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Venous obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Extrinsic compression (tumor or lymphadenopathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Increased interstitial hydrostatic pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Lymphatic obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Turner syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Noonan syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Milroy's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Lymphedema praecox",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Secondary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Lymphadenitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Granulomatous lymphangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Autoimmune disease (juvenile idiopathic arthritis &amp; Crohn's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Increased capillary permeability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Angioedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Allergic reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Hereditary angioedema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2957=[""].join("\n");
var outline_f2_56_2957=null;
var title_f2_56_2958="NHL distribution by HAART use and CD4 count";
var content_f2_56_2958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Distribution of non-Hodgkin lymphomas (NHLs) by use of HAART and CD4 cell count at diagnosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 386px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distribution of 347 NHLs by use of HAART and CD4 cell count at NHL diagnosis. CD4 cell count at diagnosis was not available for 82 NHLs.",
"    <div class=\"footnotes\">",
"     HAART: highly active antiretroviral therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2958=[""].join("\n");
var outline_f2_56_2958=null;
var title_f2_56_2959="Steeple sign";
var content_f2_56_2959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Croup: Anteroposterior radiograph with \"steeple sign\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anteroposterior (AP) view demonstrates tapering of the upper trachea, known as the \"steeple sign\" of croup. Note that the finding can be simulated by differing phases of respiration even in normal children.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_56_2959=[""].join("\n");
var outline_f2_56_2959=null;
